PROTOCOL·16 May 2026·6 min read

CJC/Ipa vs HGH-191aa — pulsatile vs direct.

Two completely different mechanisms to research the same axis: elevated growth-hormone signalling. The CJC-1295 + Ipamorelin blend uses the subject's own pituitary to release GH in physiological pulses. HGH-191aa skips that loop and delivers the molecule directly. Both are legitimate research paths — the choice depends on which part of the GH-axis your protocol is actually measuring.

The short version.

CJC-1295 / Ipamorelinblend is the physiological-rhythm option. Combining a slow GHRH analog (CJC) with a short ghrelin-receptor agonist (Ipa) prompts the pituitary to release GH in natural pulses. Downstream IGF-1 follows the body's own circadian baseline. No negative-feedback shutdown of endogenous secretion.

HGH-191aais the direct option. Recombinant, identical to native human GH. Binds GH receptors directly, no pituitary involvement. Faster effect on tissue, but long-cycle protocols can downregulate the subject's own GH axis — relevant when research scope spans > 12 weeks.

Both research reference compounds — not for human consumption.

Side-by-side.

PropertyCJC-1295 / Ipamorelin blendHGH-191aa

ClassSecretagogue blend: CJC-1295 (DAC) + IpamorelinRecombinant human growth hormone (191 amino acids)

MechanismCJC-1295 = GHRH analog, sustained · Ipamorelin = ghrelin-receptor agonist, pulse trigger. Together: pituitary releases endogenous GH in physiological pulses.Identical sequence to native human GH · binds GH receptors directly, no pituitary involvement

Release patternPulsatile · mimics natural circadian GH peaks · downstream IGF-1 follows physiological rhythmSustained · single subcut injection delivers a bolus that plateaus and decays

Application routeSubcutaneous · daily or 5×/wk research modelsSubcutaneous · daily or 5×/wk research models

Half-lifeCJC-1295 ≈ 8 days plasma · Ipamorelin ≈ 2 hours · effect is pulsatile not steady≈ 2–3 hours plasma · effect bolus-then-decay

Pituitary feedbackSubject's own pituitary stays in the loop · no shutdown risk in research modelsBypasses pituitary · exogenous GH may downregulate endogenous secretion over long protocols

Typical research dose100 µg CJC + 100 µg Ipa daily subcut (combined ~200 µg)1–4 IU daily subcut · titration up over weeks

Best atResearch models needing physiological GH rhythm, body-composition + recovery studies, longer protocolsResearch models needing precise dose control, short-cycle protocols, direct-effect studies

Variants available10 mg blend · 20 mg blend per vial10 IU · 24 IU · 36 IU per vial

Single-kit price (10 vials)from €119.90 (10 mg) · €189.90 (20 mg)from €99.90 (10 IU) · €169.90 (24 IU) · €229.90 (36 IU)

ReconstitutionBAC water · stable 28 days at 2–8 °CBAC water · stable 14–21 days at 2–8 °C · more sensitive to oxidation than peptide blends

Which one fits your research?

Pick CJC + Ipa blend if

· Long-cycle protocols (8+ weeks) where preserving the subject's endogenous GH axis matters.
· Body-composition + recovery research where physiological pulse pattern is part of the model.
· Tighter budget per research-week: 200 µg combined daily is cheap.

Shop CJC/Ipa blend →

Pick HGH-191aa alone if

· Short-cycle protocols where direct GH-receptor binding is the dependent variable.
· Precise dose-control needed (IU-level titration).
· Research is GH-receptor-mediated, not pituitary-mediated.

Shop HGH-191aa →

Stack both if

· Cross-mechanism research: pulsatile baseline + targeted bolus on top.
· Mid-cycle: blend keeps pituitary active, HGH bolus stacks short-term effects.
· Growth Protocol bundle pairs them with the 8 % bundle discount.

Growth Protocol bundle →

All compounds are research reference material — not for human consumption. Questions? Email the lab.